India's Cipla gets tentative U.S. nod for HIV tablets
MUMBAI (Reuters) - Indian drugmaker Cipla has received a tentative U.S. FDA approval for its HIV treatment tablets, which have a combination of lamivudine, nevirapine and zidovudine drugs, the drug regulator's website showed.
Cipla sells the combination drug under the brand name 'Duovir N' outside the United States.
The company plans to use a different brand name in the U.S. for this drug, S. Radhakrishnan, a director on Cipla board told Reuters.
(Reporting by Kaustubh Kulkarni; Editing by Anupama Dwivedi)
- Tweet this
- Share this
- Digg this
- Europe won't recognise vote in eastern Ukraine, Merkel tells Putin
- Kurdish peshmerga forces enter Syria's Kobani after further air strikes |
- Portugal scrambles jets again to intercept Russian bombers
- Judge rejects strict limits on U.S. nurse who treated Ebola patients |
- Test flight of Virgin Galactic spaceship ends in fatal crash in California